A. Bruss

Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases

M. Dubinsky, P. Beniwal-Patel, R. Ungaro, 2019, Digestive Diseases and Sciences.

Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.

M. Dubinsky, P. Beniwal-Patel, D. Stein, 2019, Journal of Crohn's & colitis.

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

P. Beniwal-Patel, D. Stein, A. Yarur, 2021, BMJ open gastroenterology.

Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab

D. Stein, A. Yarur, Anjali Jain, 2017 .

Vedolizumab Levels During Induction Are Associated With Remission in Patients With Inflammatory Bowel Diseases: 2017 Category Award (IBD): 2017 Presidential Poster Award: 639

M. Dubinsky, P. Beniwal-Patel, R. Ungaro, 2017 .

DOP020 Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab.

D. Stein, A. Yarur, K. Hester, 2017, Journal of Crohn's & colitis.

COMBINATION THERAPY WITH IMMUNOMODULATORS IMPROVES THE PHARMACOKINETICS OF INFLIXIMAB BUT NOT VEDOLIZUMAB OR USTEKINUMAB.

S. Targan, M. Dubinsky, P. Beniwal-Patel, 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

INFLAMMATORY BOWEL DISEASE Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab

S. Targan, P. Beniwal-Patel, D. McGovern, 2022 .